Worth reading
49Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Who is moving to which position
Resolved 14 May 2026Incoming appointee
3 itemsScheduled Appointment Date24 June 2026 (at the conclusion of the 42nd Annual General Meeting of Shareholders; subject to approval at the meeting)
Kobayashi Satoshi (小林 聡)
Previous positionExecutive Officer (General Manager, Pharmaceutical Business Division)
New positionDirector; General Manager, Pharmaceutical Business Division
生年月日 25 September 1964入社年 2021
Ashida Koichi (芦田 耕一)
Previous positionProgram Officer, Innovative Medical Technology Development Promotion Project (industry-academia-government collaborative program), Japan Agency for Medical Research and Development (currently in office)
New positionDirector (candidate for outside director)
生年月日 27 March 1963入社年 Not disclosed
Tamaki Nanako (玉置 菜々子)
Previous positionIn-house attorney, USJ LLC (currently in office)
New positionPart-time Audit & Supervisory Board Member (outside)
生年月日 22 September 1988入社年 Not disclosed
Departing officer
2 itemsDate of departure24 June 2026 (at the conclusion of the annual general meeting of shareholders)
Inoue Ryuichi (井上 隆一)Stepping down
Former PositionDirector; responsible for the Bio Business
Shigematsu Masami (重松 正巳)Stepping down
Former PositionPart-time Audit & Supervisory Board Member (outside)
Reason for departure
Expiration of term
Whether the incumbent will remain in office (whether they will retain their position)
No continuation as a director or Audit & Supervisory Board member was stated for either individual.
Shareholders’ meeting approvalYes. A proposal for the selection of candidates for company officers will be submitted to the 42nd Annual General Meeting of Shareholders, scheduled for 24 June 2026.
| Item | Details |
|---|---|
| Resolution date | 14 May 2026 |
| Scheduled Appointment Date | 24 June 2026 (at the conclusion of the 42nd Annual General Meeting of Shareholders; subject to approval at the meeting) |
| Date of departure | 24 June 2026 (at the conclusion of the annual general meeting of shareholders) |
| Name of appointee | Kobayashi Satoshi (小林 聡), Ashida Koichi (芦田 耕一), Tamaki Nanako (玉置 菜々子) |
| Appointee's new position | Director; General Manager, Pharmaceutical Business Division, Director (candidate for outside director), Part-time Audit & Supervisory Board Member (outside) |
| Appointee's previous position | Executive Officer (General Manager, Pharmaceutical Business Division), Program Officer, Innovative Medical Technology Development Promotion Project (industry-academia-government collaborative program), Japan Agency for Medical Research and Development (currently in office), In-house attorney, USJ LLC (currently in office) |
| Appointee's date of birth | 25 September 1964, 27 March 1963, 22 September 1988 |
| Year the appointee joined the Company | 2021, Not disclosed, Not disclosed |
| Name of departing officer | Inoue Ryuichi (井上 隆一), Shigematsu Masami (重松 正巳) |
| Former position of departing officer | Director; responsible for the Bio Business, Part-time Audit & Supervisory Board Member (outside) |
| Reason for departure | Expiration of term |
| Whether the incumbent will remain in office | No continuation as a director or Audit & Supervisory Board member was stated for either individual. |
| Subject to Approval by the General Meeting of Shareholders | Yes. A proposal for the selection of candidates for company officers will be submitted to the 42nd Annual General Meeting of Shareholders, scheduled for 24 June 2026. |
Items this document does not state (8)
Number of shares held by the appointeeNew position of departing officerReason for changeReasons for appointmentNumber of directors after the changeFiling as an independent officerDetails of organizational changesChange in Corporate Governance Structure
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.No specific explanation was provided for the selection or retirement. It was stated that 1 director and 1 Audit & Supervisory Board member will retire upon expiration of their terms.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.